FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131883755> ?p ?o ?g. }

• W3131883755 endingPage "55" @default.
• W3131883755 startingPage "PS9" @default.
• W3131883755 abstract "Abstract Background: Recently, the FeDeriCa trial investigated a fixed-dose combination (FDC) of Perjeta and Herceptin (PH), administered by subcutaneous (SC) injection, and demonstrated non-inferior pharmacokinetics of serum Perjeta and Herceptin levels compared to PH IV, along with a similar efficacy and safety profile to the intravenous (IV) administration of PH. In Canada, the standard of care for first-line HER2-positive metastatic breast cancer (mBC) is PH plus taxane chemotherapy with PH until disease progression. Currently, PH are administered as sequential IV infusions. SC administration of PH FDC has the potential to relieve pressure on the healthcare system, decrease treatment burden, and improve the patient experience. Objective: To estimate the incremental costs/savings, including time savings, associated with the use of PH FDC SC for the treatment of HER2+ mBC, if reimbursed with the same provincial funding criteria as PH IV in Ontario and Quebec, Canada. Methods: An Excel-based budget impact model was developed to determine the economic impact of PH FDC SC in comparison to PH IV in Ontario and Quebec. Direct medical costs in the analysis included drug acquisition, drug preparation and administration, and systemic therapy infusion chair/suite costs. Nurse and pharmacist wages were obtained from the Government of Canada’s Job Bank. Systemic therapy infusion chair/suite costs were derived from literature. Data related to time associated with preparation and administration of PH FDC SC and PH IV were collected through a survey completed by nurses and pharmacists involved in the FeDeriCa clinical trial in Canada. Results: HER2+ mBC patients treated with PH FDC SC generate net cost savings to the health system compared to treatment with PH IV. These cost savings to the health system are generated due to fewer costs associated with drug acquisition, pharmacist and nurse wages directed towards drug preparation and administration respectively, as well as fewer overhead costs associated with the infusion chair/suite for PH FDC SC compared to PH IV. The use of PH FDC SC provides the healthcare payer with the opportunity to optimize drug and medical resources appropriately while offering a therapy that is aligned with patient and clinician preferences. Citation Format: Kaushik Sripada, Siddhi Manjrekar, Kristoph Klein-Panneton, Megan Coombes, Cristiano Ferrario. Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-55." @default.
• W3131883755 created "2021-03-01" @default.
• W3131883755 creator A5021747199 @default.
• W3131883755 creator A5026774205 @default.
• W3131883755 creator A5034804495 @default.
• W3131883755 creator A5049035942 @default.
• W3131883755 creator A5057680995 @default.
• W3131883755 date "2021-02-15" @default.
• W3131883755 modified "2023-09-27" @default.
• W3131883755 title "Abstract PS9-55: Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis" @default.
• W3131883755 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps9-55" @default.
• W3131883755 hasPublicationYear "2021" @default.
• W3131883755 type Work @default.
• W3131883755 sameAs 3131883755 @default.
• W3131883755 citedByCount "0" @default.
• W3131883755 crossrefType "journal-article" @default.
• W3131883755 hasAuthorship W3131883755A5021747199 @default.
• W3131883755 hasAuthorship W3131883755A5026774205 @default.
• W3131883755 hasAuthorship W3131883755A5034804495 @default.
• W3131883755 hasAuthorship W3131883755A5049035942 @default.
• W3131883755 hasAuthorship W3131883755A5057680995 @default.
• W3131883755 hasConcept C112705442 @default.
• W3131883755 hasConcept C121608353 @default.
• W3131883755 hasConcept C126322002 @default.
• W3131883755 hasConcept C143998085 @default.
• W3131883755 hasConcept C2775930923 @default.
• W3131883755 hasConcept C2777511904 @default.
• W3131883755 hasConcept C2779786085 @default.
• W3131883755 hasConcept C2781164504 @default.
• W3131883755 hasConcept C530470458 @default.
• W3131883755 hasConcept C71924100 @default.
• W3131883755 hasConceptScore W3131883755C112705442 @default.
• W3131883755 hasConceptScore W3131883755C121608353 @default.
• W3131883755 hasConceptScore W3131883755C126322002 @default.
• W3131883755 hasConceptScore W3131883755C143998085 @default.
• W3131883755 hasConceptScore W3131883755C2775930923 @default.
• W3131883755 hasConceptScore W3131883755C2777511904 @default.
• W3131883755 hasConceptScore W3131883755C2779786085 @default.
• W3131883755 hasConceptScore W3131883755C2781164504 @default.
• W3131883755 hasConceptScore W3131883755C530470458 @default.
• W3131883755 hasConceptScore W3131883755C71924100 @default.
• W3131883755 hasIssue "4_Supplement" @default.
• W3131883755 hasLocation W31318837551 @default.
• W3131883755 hasOpenAccess W3131883755 @default.
• W3131883755 hasPrimaryLocation W31318837551 @default.
• W3131883755 hasRelatedWork W2163622510 @default.
• W3131883755 hasRelatedWork W2767649763 @default.
• W3131883755 hasRelatedWork W2944154894 @default.
• W3131883755 hasRelatedWork W2962970029 @default.
• W3131883755 hasRelatedWork W3010153683 @default.
• W3131883755 hasRelatedWork W3088751691 @default.
• W3131883755 hasRelatedWork W3123611170 @default.
• W3131883755 hasRelatedWork W3173641743 @default.
• W3131883755 hasRelatedWork W4281733293 @default.
• W3131883755 hasRelatedWork W4287922124 @default.
• W3131883755 hasVolume "81" @default.
• W3131883755 isParatext "false" @default.
• W3131883755 isRetracted "false" @default.
• W3131883755 magId "3131883755" @default.
• W3131883755 workType "article" @default.